Compare Bristol-Myers Squibb Co (BMY) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Infosys Limited — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Infosys Limited trades at $11.05 (market cap $46.90B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.5× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| BMY | INFY | |
|---|---|---|
Market Cap | $116.30B | $46.90B |
Sector | Health | Technology |
52-Week High | $62.37 | $20.22 |
52-Week Low | $42.60 | $10.49 |
Enterprise Value | $152.24B | $44.12B |
Dividend Yield | 4.42% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
INFY trades at $11.50, up 5.12% today, with a bullish technical signal and strong profitability metrics including a 16.44% net income margin and 31.57% ROE. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company is actively expanding AI collaborations in healthcare and financial services, as reported by PRNewsWire on June 24, 2026.
The stock offers a moderate valuation with a P/E of 13.81 and consensus price target of $12.14, suggesting modest upside. Risks include competitive pressures from AI automation and volatile IT spending, but institutional sentiment is mixed with 37.5% buy ratings. The dividend yield adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
